Drug Discovery World

JANUARY 30, 2024

Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was awarded a Lifetime Achievement Award in recognition of ‘extraordinary contributions to gene therapy’, a field he has helped shape through his pioneering work on lentiviral vectors.

Therapies 180

Therapies Clinical Trials Trials Production 180

Drug Discovery World

SEPTEMBER 20, 2023

A new cooperative network designed to foster collaboration and boost the sharing of knowledge and expertise for the UK’s advanced therapies sector has been launched. Matthew Durdy, Chief Executive of the CGT Catapult, said:   “Scotland has a strong life sciences sector.

Therapies 277

Therapies Science Vaccine Production 277

Drug Discovery World

OCTOBER 18, 2023

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies.

Therapies 163

Therapies Clinical Trials FDA Approval Virus 163

DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 82

Drug Development Clinical Trials Drugs Therapies 82

Drug Discovery World

APRIL 23, 2024

Given the increased awareness of concussion and the associated long-term sequela from concussive injury it is imperative that we accelerate drug development efforts to find an effective therapy. Tremendous strides have been made with other diseases, yet there are still no FDA-approved drug therapies for TBI.

Therapies 148

Therapies Drugs Laboratories Medical Schools 148

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. These may provide an opportunity for treatment for post-Covid-19 cognitive impairment.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

Drug Discovery World

AUGUST 30, 2022

The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. Creating a sustainable cell & gene therapy company.

Therapies 246

Therapies Hospitals Clinical Trials Clinical Development 246

Drug Discovery World

JANUARY 30, 2023

Register to attend Cell and gene therapy: sustaining growth and maximising opportunities, a free-to-attend DDW webinar, supported by Benchling and BPS Bioscience, on February 17, 2023 at 8am PST / 11am EST / 4pm GMT / 5pm CET. Cell and gene therapies (CGT) are transforming the way diseases are treated.

Disease 130

Disease Treatment Therapies Drug Development 130

Drug Discovery World

DECEMBER 8, 2023

Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The cell and gene therapy industry is no exception to this digital transformation. It is imperative for the industry to communicate the precise composition and attributes of these therapies to regulatory bodies.

Therapies 163

Therapies Clinical Trials Small Molecule Production 163

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

OCTOBER 31, 2023

Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. Currently, 15 trials of the new potential therapies for ALS have included NfL as an endpoint 8.

Drug Development 148

Drug Development Disease Drugs Clinical Trials 148

Drug Discovery World

AUGUST 4, 2023

Dr Christian K Schneider , Head of Biopharma Excellence at PharmaLex, presents the findings of an industry panel debate on barriers to commercialisation of novel treatments, and the most effective strategies to bring them to market. Other challenges involve talent gaps, particularly now that cell and gene therapy manufacturing is maturing.

Therapies 130

Therapies Pharma Companies Treatment Marketing 130

Drug Discovery World

JANUARY 19, 2024

The multicentre, open-label, non-randomised study aimed to understand the safety and efficacy of BPM31510 delivered intravenously in conjunction with gemcitabine as a second- or third-line therapy for advanced pancreatic cancer. Among study participants, median progression free survival was 7.2 months (range: 3.8 months – 10.5

Therapies 130

Therapies Clinical Trials Trials Treatment 130

Drug Discovery World

MAY 9, 2023

Jantzen Sperry , PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. Fewer than 5% of oncology drugs that enter clinical trials in the US receive US FDA approval.

Drug Development 130

Drug Development Clinical Trials Animal Testing Cell Based Assays 130

Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD in 2023 to $166.53 billion USD by 2028.

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

DrugBank

JUNE 6, 2024

In the rapidly evolving landscape of oncology drug development, artificial intelligence (AI) has emerged as a revolutionary force, altering not just the pace but the very methodology of discovery and development.   What sets RADR ® apart is its robust data-driven approach.

Drug Development 74

Drug Development Clinical Trials Drugs Therapies 74

Drug Target Review

AUGUST 7, 2024

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

Drug Development 59

Drug Development Clinical Pharmacology Clinical Trials Packaging 59

Drug Discovery World

JANUARY 24, 2023

There are currently no cures for either disease, but researchers hope that these results will significantly speed up the search for new treatments. Tracking the progression of FA and DMD is normally done through intensive testing in a clinical setting. Image shows: Luchen Li, wearing the sensor suit, and Professor Aldo Faisal.

Drug Development 130

Drug Development Clinical Trials Trials Disease 130

PPD

SEPTEMBER 25, 2023

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

Drug Discovery World

AUGUST 16, 2024

The chosen news highlights this week all feature advances in drug development in oncology indications and reflect the breadth of therapeutic approaches to cancer treatment. News round-up for 12-16 August by DDW Senior Digital Content Editor Diana Spencer. First claudin 18.2 monoclonal antibody.

Licensing 148

Licensing Licensing Drugs Clinical Trials 148

Drug Discovery World

SEPTEMBER 6, 2022

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. Record breaking investments in 2021 fuel an industry on fire . billion raised.

Therapies 130

Therapies Clinical Trials Production Disease 130

Drug Discovery World

JUNE 19, 2023

Anoat Therapeutics’ goal is to bring a transformative and mutation-agnostic treatment option to CF patients for whom existing therapies are not effective – for example, patients not eligible or responsive to CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator therapies.

Therapies 130

Therapies Science Regulations Treatment 130

Drug Discovery World

JANUARY 25, 2023

Vésale Bioscience, a company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, has received €1.8 The project is a phagogram using artificial intelligence (AI) that enables decentralised diagnostics and personalised treatment.

Therapies 130

Therapies Hospitals Treatment Research 130

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. Advances in understanding treatment resistant cancer cells (part 1).

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Drug Discovery World

FEBRUARY 14, 2023

The initial focus will be on urological and gastrointestinal cancers where there is a major need to bring novel treatments to more cancer patients. Sean McClain, Founder and CEO of Absci, said: “Currently, it takes about ten years and costs over $1 billion to bring one drug to market for patients.

Therapies 130

Therapies Clinical Trials Trials Drug Development 130

Drug Discovery World

OCTOBER 4, 2022

The US Food and Drug Administration (FDA) has granted approval to AMX0035, a new treatment for people living with amyotrophic lateral sclerosis (ALS). Development of the drug was funded by $2.2 We still have a lot of work to do to cure ALS, but this new treatment is a significant step in that fight.” .

FDA Approval 130

FDA Approval FDA Treatment Clinical Trials 130

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Discovery World

MARCH 14, 2023

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest.

Disease 130

Disease Treatment Science Clinical Development 130

Drug Target Review

NOVEMBER 29, 2023

Our primary focus is to design and develop RNA therapies for liver diseases. Our team of chemists then uses this information to develop novel therapies. By doing this, we get a superior understanding of which therapies will and will not work in human biology before a clinical trial.

Therapies 102

Therapies Disease RNA Engineering 102

Fierce BioTech

APRIL 3, 2024

Mini-Organs, Major Breakthroughs: How Hub Organoids Are Accelerating Oncology Drug Development dwunderlin Wed, 04/03/2024 - 17:28 Tue, 05/14/2024 - 09:30 Resource Type Webinar Dr. Sylvia F. png Listing Introduction Predict patient response to treatment with patient-derived organoids. Click here to login.

Drug Development 52

Drug Development Drugs Therapies Treatment 52

Drug Discovery World

JULY 1, 2024

The same spatial mapping will also enable Nucleai’s applications to serve as companion diagnostics that match patients to the most effective treatment. “Today’s advanced therapies require advanced diagnostics,” said David West, Proscia’s CEO.

Clinical Trials 163

Clinical Trials Laboratories Trials Treatment 163

Drug Discovery World

JUNE 28, 2024

This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as the launch of DDW’s latest In Focus report.

Clinical Trials 130

Clinical Trials Drugs Trials Virus 130

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. Could you give us an overview of the Lineage platform?

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

PPD

JUNE 27, 2024

As the search for treatments for alopecia areata continues, it’s important for drug developers to understand the key pillars of several dermatology indications: the consistency of endpoints and the intrasite and intersite variability for raters’ assessed endpoints. Accelerate your alopecia areata treatments.

Treatment 52

Treatment Clinical Trials Small Molecule Clinical Research 52

Drug Discovery World

DECEMBER 1, 2023

The key drug discovery news this week focuses on experimental approaches to the treatment of some of the most challenging diseases, including a mathematical model that can simulate Alzheimer’s progression and using CRISPR gene editing to ‘shred’ tumours. Can a plant-based discovery pave the way for new drug treatments?

Therapies 130

Therapies Drugs Disease International 130

PLOS: DNA Science

MARCH 28, 2024

A new drug has entered the arsenal against Duchenne muscular dystrophy (DMD), a genetic disease that affects boys and is challenging to treat. FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. In 2023, two gene-based treatments became available.

FDA Approval 75

FDA Approval Treatment FDA DNA 75